Drug Development

Top-level science through the eyes of an expert.Preclinical evaluation of an energy-driven device for localized skin delivery of nucleic acidsJoin us for the next session in Genoskin’s webinar series, where we explore how an energy-driven, microneedle-based device enables localized, non-viral delivery of naked nucleic acids to skin, with preclinical in vivo and ex vivo data highlighting transgene expression, immune activation,Read more

Request a toxicity pilot study plan and quote to evaluate local tolerance and immune effects in ex vivo human skin models.

Prove ADCC Activityin real human skinFor therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential.Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear. HypoSkin® offers a solution Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platform to confirm theRead more

Explore how HypoSkin®—a standardized, injectable, and immunocompetent human skin model—provides a translational, animal-free solution for assessing the immunogenicity of therapeutic compounds. From structural stability to real-time immune response profiling, this white paper delivers data-backed insights designed for pharma and biotech teams advancing injectable drug development.

Top-level science through the eyes of an expert.Join us for the next session of Naked Immunology Webinar series, where we explore cutting-edge advancements in drug delivery and therapeutic innovation. In this session we will discuss how the immune system’s reaction to neuromuscular blockers could offer new therapeutic insights. WATCH NOWThis webinar explores new insights into the antibody responses of patientsRead more

Vaccine DevelopmentVaxSkin® an innovative platform to study vaccine immunogenicityIntroduction The field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials. Developing safe and effective vaccines requires a clear understanding of early immune responses at the injectionRead more